Valuation: Arcutis Biotherapeutics, Inc.

Market Cap 3.34B 2.88B 2.71B 2.46B 4.63B 320B 4.7B 31.8B 12.46B 160B 12.52B 12.25B 532B P/E 2026 *
68.3x
P/E 2027 * 21.2x
Enterprise Value 3.05B 2.63B 2.48B 2.25B 4.23B 292B 4.3B 29.05B 11.38B 146B 11.44B 11.19B 486B EV / Sales 2026 *
5.68x
EV / Sales 2027 * 3.94x
Free-Float
98.22%
Yield 2026 *
-
Yield 2027 * -
1 day+3.63%
1 week+1.18%
Current month-1.19%
1 month-6.84%
3 months+32.50%
6 months-0.64%
Current year-8.61%
1 week 25.28
Extreme 25.28
26.71
1 month 24.76
Extreme 24.76
29.24
Current year 19.3
Extreme 19.295
30.75
1 year 15.1
Extreme 15.1
31.77
3 years 1.76
Extreme 1.76
31.77
5 years 1.76
Extreme 1.76
31.77
10 years 1.76
Extreme 1.76
40.88
Manager TitleAgeSince
Chief Executive Officer 58 31/03/2017
Corporate Officer/Principal 71 02/12/2025
Director of Finance/CFO - 14/05/2025
Director TitleAgeSince
Chairman 55 30/11/2019
Director/Board Member 58 31/12/2015
Director/Board Member 74 31/07/2020
Date Insider Type Main position Quantity % Market Cap.
12/08/26 Fiscal year

Chief Technology Officer

20,100 0.0161%
03/08/26 Sell

Chief Technology Officer

-955 0.0008%
03/08/26 Sell

General Counsel

-1,230 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
+3.63%+1.18%+58.54%+239.39% 3.34B
+0.53%+1.66%+41.18%-0.27% 80.91B
-1.10%-4.85%-3.14%+29.15% 50.13B
+0.09%-2.03%+12.88%+166.63% 47.97B
+5.49%+20.25%-26.17%-37.62% 53.62B
+1.63%+4.25%+56.39%-18.61% 31.41B
-2.33%+3.95%+124.14%-38.04% 25.14B
-0.02%+1.98%+45.40%+92.80% 25.03B
+1.66%+2.83%+0.51%+215.41% 21.45B
+0.56%+4.81%+66.86%+127.19% 16.93B
Average +0.99%+2.47%+37.66%+77.60% 35.59B
Weighted average by Cap. +0.93%+2.41%+27.41%+44.31%

Financials

2026 *2027 *
Net sales 537M 464M 436M 397M 746M 51.45B 757M 5.12B 2.01B 25.73B 2.02B 1.97B 85.71B 686M 592M 557M 506M 952M 65.68B 966M 6.53B 2.56B 32.85B 2.57B 2.52B 109B
Net income 51.79M 44.73M 42.09M 38.25M 71.94M 4.96B 73M 494M 193M 2.48B 194M 190M 8.27B 168M 145M 136M 124M 233M 16.09B 237M 1.6B 627M 8.05B 630M 617M 26.8B
Net Debt -288M -249M -234M -213M -401M -27.63B -406M -2.75B -1.08B -13.82B -1.08B -1.06B -46.03B -638M -551M -518M -471M -886M -61.11B -899M -6.08B -2.38B -30.56B -2.39B -2.34B -102B
Logo Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.
Employees
354
Date Price Change Volume
18/08/26 US$26.54 +3.63% 1,972,077
17/08/26 US$25.61 -2.21% 1,710,163
14/08/26 US$26.19 +1.39% 1,109,513
13/08/26 US$25.83 -1.71% 1,585,686
12/08/26 US$26.28 +0.19% 1,184,073
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
26.54USD
Average target price
36.88USD
Spread / Average Target
+38.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARQT Stock